- $769.77m
- $429.83m
- $91.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 22.63 | ||
| Price to Tang. Book | 22.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.53% | ||
| Return on Equity | -343.83% | ||
| Operating Margin | -89.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 75 | 63.17 | 10.29 | 17.16 | 91.28 | 65.67 | 81.69 | 62.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Directors
- James Topper NEC (59)
- Hamza Suria PRE (44)
- Dennis Mulroy CFO (66)
- Eric Loumeau COO (58)
- Paul Lizzul OTH (46)
- Hollings Renton LED (74)
- Daniel Faga DRC (41)
- Dennis Fenton IND (69)
- Laura Hamill IND (56)
- Magda Marquet IND (62)
- Oleg Nodelman IND (44)
- John Schmid IND (58)
- J. Anthony Ware IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- November 16th, 2005
- Public Since
- January 26th, 2017
- No. of Shareholders
- 7
- No. of Employees
- 136
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 29,380,496
- Address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, 92121
- Web
- https://www.anaptysbio.com/
- Phone
- +1 8583626295
- Auditors
- KPMG LLP
Upcoming Events for ANAB
Q3 2025 AnaptysBio Inc Earnings Release
Similar to ANAB
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the AnaptysBio share price?
As of Today at 19:16 UTC, shares in AnaptysBio are trading at $26.20. This share price information is delayed by 15 minutes.
How has the AnaptysBio share price performed this year?
Shares in AnaptysBio last closed at $26.20 and the price had moved by -13.59% over the past 365 days. In terms of relative price strength the AnaptysBio share price has underperformed the S&P500 Index by -22.48% over the past year.
What are the analyst and broker recommendations for AnaptysBio?
The overall consensus recommendation for AnaptysBio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AnaptysBio dividend yield?
AnaptysBio does not currently pay a dividend.
Does AnaptysBio pay a dividend?
AnaptysBio does not currently pay a dividend.
When does AnaptysBio next pay dividends?
AnaptysBio does not currently pay a dividend.
How do I buy AnaptysBio shares?
To buy shares in AnaptysBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AnaptysBio?
As of the previous close price of $26.20, shares in AnaptysBio had a market capitalisation of $769.77m.
Where are AnaptysBio shares listed?
Here are the trading details for AnaptysBio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ANAB
What kind of share is AnaptysBio?
Based on an overall assessment of its quality, value and momentum AnaptysBio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AnaptysBio share price forecast for 2025?
The analyst consensus target price for shares in AnaptysBio is $42.60. That is 62.6% above the last closing price of $26.20.
Analysts covering AnaptysBio currently have a consensus Earnings Per Share (EPS) forecast of -$5.30 for the next financial year.
Find out moreWhat is the trend in the AnaptysBio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AnaptysBio. Over the past six months, its share price has outperformed the S&P500 Index by +71.9%.
As of the last closing price of $26.20, shares in AnaptysBio were trading +23.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AnaptysBio PE Ratio?
The AnaptysBio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $26.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AnaptysBio?
AnaptysBio's management team is headed by:
- James Topper - NEC
- Hamza Suria - PRE
- Dennis Mulroy - CFO
- Eric Loumeau - COO
- Paul Lizzul - OTH
- Hollings Renton - LED
- Daniel Faga - DRC
- Dennis Fenton - IND
- Laura Hamill - IND
- Magda Marquet - IND
- Oleg Nodelman - IND
- John Schmid - IND
- J. Anthony Ware - IND